1. Home
  2. >
  3. Stock Markets 🤑
Posted

Weight Loss Drug Boom Benefits Pharma Giants But Could Hit Junk Food Industry

  • Novo Nordisk and Eli Lilly stand to benefit as sales of their GLP-1 drugs like Ozempic and Wegovy ramp higher.

  • Suppliers like Catalent and Thermo Fisher have been tapped to help manufacture the injections to meet demand.

  • Athletic brands like Nike, Lululemon, and Planet Fitness could attract more customers as patients pair weight loss with exercise.

  • Medical device companies like Tandem Diabetes and ResMed face lower demand as obesity and sleep apnea improve.

  • Fast food chains and junk food companies could see reduced revenue if customers cut back on unhealthy foods.

businessinsider.com
Relevant topic timeline:
Main Topic: Investigation into the potential risk of self-injury and suicidal thoughts associated with the use of Ozempic and Wegovy, drugs used to lower blood sugar and suppress appetite. Key Points: 1. Health regulators in Europe and the UK are reviewing reports of self-injury and suicidal thoughts among individuals taking Ozempic and Wegovy. 2. Clinical trials have not shown evidence of an increased risk of these side effects, but the US FDA requires a warning for weight management medications that work on the central nervous system. 3. Some patients have reported severe psychological reactions to GLP-1 receptor agonists, but doctors and clinical trials have not observed a clear trend or correlation between the drugs and these side effects.
Main Topic: Lawsuit alleges that Novo Nordisk and Eli Lilly failed to adequately warn patients about the risk of severe stomach problems associated with their diabetes drugs Ozempic and Mounjaro. Key Points: 1. Lawsuit claims that the drugs can cause gastrointestinal injuries, including severe gastroparesis and persistent vomiting. 2. GLP-1 agonists like Ozempic and Mounjaro can slow down food movement through the stomach, leading to feelings of fullness, but can also cause gastrointestinal issues. 3. Over 400 people have come forward claiming gastrointestinal injuries from the drugs, and the lawsuit expects thousands of similar cases.
Main Topic: The obesity drug Wegovy reduces the risk of cardiovascular events by 20%. Key Points: 1. Wegovy, a weight-loss drug, has been found to have medical benefits beyond weight reduction. 2. The drug cuts the risk of cardiovascular events, such as heart attack and stroke, by 20%. 3. The results may lead to insurance companies providing coverage for Wegovy, which is currently perceived as a lifestyle medication.
Novo Nordisk plans to launch its weight-loss drug Wegovy in more countries, despite shortages caused by high demand, according to CEO Lars Fruergaard Jorgensen.
The Danish pharmaceutical company Novo Nordisk, known for its weight loss drugs Ozempic and Wegovy, is driving most of Denmark's recent economic growth and has become the second most valuable public company in Europe.
Novo Nordisk briefly surpassed LVMH to become Europe's most valuable company on the back of its weight loss drugs, but LVMH regained the top spot, although Novo Nordisk remains close behind with its highly anticipated drugs.
The rise of diabetes and weight loss drugs like Ozempic is not only impacting pharmaceutical companies, but also retailers, makers of weight loss products, and other industries, with knock-on effects ranging from increased foot traffic in stores and changing consumer behavior to potential disruptions in the diet industry.
Novo Nordisk has launched its weight-loss drug Wegovy in the UK, but warns of ongoing supply shortages that may take years to resolve.
Weight-loss drugs are becoming increasingly popular and are expected to have a significant impact on the pharmaceutical industry.
GLP-1 agonists, such as Ozempic and Wegovy, used to treat diabetes and weight loss have shown potential in reducing cravings for alcohol, nicotine, opioids, and compulsive behaviors, although more research is needed to confirm their effectiveness as addiction treatments.
The sale of anti-obesity drugs in Denmark, particularly Ozempic and Wegovy, has significantly boosted the country's economy and prevented it from entering a recession, with the pharmaceutical industry adding almost two percentage points of growth to the GDP in the first half of 2023. The success of these drugs has also made Novo Nordisk, the company behind them, the highest valued company in Europe.
Ypsomed has announced a long-term supply deal with Novo Nordisk for autoinjectors, indicating the success of Novo Nordisk's weight-loss drug business and the potential for growth in the obesity market.
Anti-obesity drugs developed by Novo Nordisk and Eli Lilly have the potential to transform public health but could also disrupt industries such as food, fitness, and healthcare, affecting companies like Nestlé and McDonald's.
The introduction of weight-loss drugs like Wegovy could lead to a healthcare crisis, as the cost and demand for these medications may overwhelm insurers, employers, and government programs that purchase medications in the United States.
The demand for diabetes and obesity drugs, such as Ozempic and Wegovy, has increased by 300% in the last two years, with Ozempic accounting for 65% of total prescriptions due to its off-label use for weight loss, but future prescription volumes will depend on supply shortages and other factors.
The FDA has updated the label for weight-loss drugs Ozempic and Wegovy, acknowledging reports of blocked intestines as a possible side effect, although they have not directly linked the condition to the medications.
Drugmakers spent nearly $500 million on advertisements for obesity and diabetes treatments in the U.S. during the first seven months of this year, with Novo Nordisk's Ozempic and Wegovy leading the pack.
Structure Therapeutics' stock rises as its obesity pill shows potential to challenge pharmaceutical giants like Lilly and Novo in the market for new obesity medicines.
Novo Holdings, the controlling shareholder of Novo Nordisk, could receive a significant windfall from the success of weight-loss drug Wegovy, potentially making it a major philanthropist and ESG investor.
The popularity and usage of weight-loss drugs like Ozempic are causing a decrease in sales for snack makers as customers on these medications are cutting back on high-fat and salty treats due to appetite suppression.
Coca-Cola shares fell as weight-loss drugs like Ozempic and Wegovy are causing customers to buy fewer groceries and consume fewer calories, leading to concerns in the industry.
The high demand for weight loss drugs like Wegovy and Mounjaro has exceeded the capacity of drugmakers to manufacture them, creating shortages and potential supply strain for treating obesity.
Anti-diabetic drugs like Ozempic and Wegovy, known for their weight loss effects, are causing shoppers to reduce their grocery purchases, leading to stock drops for beer and snack distributors such as Nestle, Mondelez International, and Kraft Heinz.
PepsiCo CEO Ramon Laguarta stated that the company has experienced negligible impact on its business from weight loss and diabetes drugs like Ozempic and Wegovy, but is closely monitoring their growth, as long-term adoption of these drugs could significantly change consumer habits and impact food companies.
It is uncertain how GLP-1 diabetes and weight loss drugs will impact Walmart and PepsiCo's stocks, but Jim Cramer suggests that it may be risky to invest in companies that sell food if their stock portfolios are at risk of an earnings miss.
Novo Nordisk's stock surged after suggesting that its diabetes drug, Ozempic, may have the potential to treat chronic kidney disease, causing stocks of dialysis providers DaVita and Fresenius to plummet.
Shares of pharmaceutical company Eli Lilly are on the rise, driven by the growth potential of its diabetes and obesity products, leading analysts to predict that it could become the first trillion-dollar bio-pharma company. The company's recent approval of Mounjaro for treating type 2 diabetes has resulted in strong revenue growth, and there is anticipation that it will also gain FDA approval for treating obesity. Wall Street analysts are optimistic about Eli Lilly stock, with a consensus rating of Strong Buy.
Novo Nordisk has raised its full-year sales and operating profit outlook for the third time this year due to strong demand for its weight-loss drug Wegovy and diabetes medication Ozempic in the United States, leading to a record-high in its shares.
The popularity of weight-loss supplement Ozempic is impacting Walmart, with data showing a slight pullback in overall basket from those who take the drug, although shoppers on Ozempic are actually spending more money at the retailer, primarily in other categories such as health and wellness. This suggests that the cohort of people taking Ozempic and similar medications has not yet offset the rest of the customer base when it comes to food shopping.